Local Solutions, Global Impact

GAIA Vaccine Foundation Sponsors Groundbreaking Mali mRNA Project

November 17, 2026

Dear GAIA Supporters,

We are thrilled to share a momentous milestone in our ongoing mission to promote global wellness and equitable care. GAIA Vaccine Foundation (GAIA VF) is serving as the fiscal sponsor for a groundbreaking project led by the health research center CRSGlobale to establish Mali’s very first mRNA vaccine manufacturing capacity!

Local vaccine production will empower Mali and the Sahel region to respond swiftly to outbreaks with domestically produced doses, rather than depending on external supply chains that deprioritize lower-income countries in times of crisis. During COVID-19, for instance, Mali waited months while nearly all advanced doses were produced overseas.

Through a fiscal sponsorship agreement, GAIA VF is supporting the 12-month start-up phase (2026–2027) through a $150,000 grant request to fund core staff, office, and lab facilities in the cities of Bamako and Koulikoro.

To drive this initiative, CRSGlobale has partnered with EVA Therapeutics, using their Providence-based computational vaccine designs as the manufacturing "recipes" in Mali. Designs are already underway for Bundibugyo Ebola, Lassa fever, and universal influenza, alongside preparations for local trial sites for an innovative mRNA mpox vaccine.

This is a decisive step toward Mali's first mRNA manufacturing facility, beginning with early-stage human trial vaccines made right in West Africa.

We couldn't be more excited for what lies ahead! Thank you for your continued belief in our vision, and here's to making history together!

Be a part of this exciting project by donating to GAIA VF!

With gratitude,

The GAIA Vaccine Foundation Team